From Wikipedia, the free encyclopedia

[1] [2] [3] [4] [5] [6] [7] [8]

Saxenda and Liraglutide

Saxenda is an injectable medication that is recommended for those patients (adults) who are overweight or suffer from other related diseases such as obesity.

The injection is the injectable presentation for the medication liraglutide, which is used to treat blood sugar disorders in patients, the majority of whom are obese or diabetics.

Liraglutide is a drug that is designed to control and manage sugar levels within an individual, it is used to medicate and help people with type 2 diabetes or obesity.

Obesity

Obesity is a chronic illness that has harmed hundreds of people for a long time. It is the buildup of fat within the human body that is detrimental to one's health.

Consequences or Negative effects:

Like all medications, this one has consequences or side effects when stopped, even though it has helped a lot of people.

Digestive Problems

In the Journal of Endocrinology, Metabolism and Diabetes of South Africa, [9] according to L. Lambert, "During clinical trials, gastrointestinal reactions were the most commonly reported adverse reactions." These consist of constipation, diarrhea, vomiting, and nausea.

Rebound effect / Weight gaining

In the Medicine Matters - Diabetes website, [10] they discussed how Bodyweight rebounds after the withdrawal of the medication:

“The researchers found that people who lost the most weight while taking semaglutide tended to then regain the most after stopping it, although they still retained a larger reduction from baseline than participants who had lost less weight during the treatment period.”

The issue with this medication is that, [11] similar to other medicines, it does not work like magic; instead, the effectiveness of the medication depends on how well the person taking it is managing it. Long-term medication effects end, and maintaining your well-being depends entirely on maintaining a regular schedule and leading a balanced, healthy life. After stopping the medication, the rebound effect happens in people who do not follow a healthy diet and routine.


  1. ^ "Can You Maintain Weight-Loss After Saxenda?". www.ukmeds.co.uk. Retrieved 2 February 2024.
  2. ^ Goodman, Brenda (5 October 2023). "Researchers link popular weight loss drugs to serious digestive problems for 'hundreds of thousands' worldwide". CNN. Retrieved 1 February 2024.
  3. ^ Henderson, Laura (23 January 2023). O'Loan, James (ed.). "The Side Effects of Stopping Saxenda | Withdrawal Symptoms". myBMI. Retrieved 1 February 2024.
  4. ^ McDermid, Eleanor. "Bodyweight rebounds after semaglutide withdrawal". diabetes.medicinematters.com. Retrieved 1 February 2024.
  5. ^ Romantsova, Tatiana Ivoanova (25 April 2018). "Analog glyukagonopodobnogo peptida-1 liraglutid (Saksenda®): mekhanizm deystviya, effektivnost' v lechenii ozhireniya" Аналог глюкагоноподобного пептида-1 лираглутид (Саксенда®): механизм действия, эффективность в лечении ожирения [Glucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, effectiveness in the treatment of obesity]. Ožirenie i Metabolizm. 15 (1): 3–11. doi: 10.14341/omet201813-11. Retrieved 2024-02-01.
  6. ^ "Prescription Weight-Loss Medicine | Saxenda® (liraglutide) injection 3mg". www.saxenda.com. Retrieved 1 February 2024.
  7. ^ Nuffer, Wesley A.; Trujillo, Jennifer M. (October 2015). "Liraglutide: A New Option for the Treatment of Obesity". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 35 (10): 926–934. doi: 10.1002/phar.1639. PMID  26497479. S2CID  23968739.
  8. ^ Kelly, Aaron S.; Auerbach, Pernille; Barrientos-Perez, Margarita; Gies, Inge; Hale, Paula M.; Marcus, Claude; Mastrandrea, Lucy D.; Prabhu, Nandana; Arslanian, Silva (28 May 2020). "A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity". New England Journal of Medicine. 382 (22): 2117–2128. doi: 10.1056/NEJMoa1916038. ISSN  0028-4793. PMID  32233338.
  9. ^ Lambert, L (2021). "Focus on Saxenda® solution for injection". Journal of Endocrinology, Metabolism and Diabetes of South Africa. 25.1 (2021): 8–10. doi: 10.1056/NEJMoa1916038. PMID  32233338. Retrieved 2 February 2024.
  10. ^ McDermid, Eleanor (9 May 2022). "Bodyweight rebounds after semaglutide withdrawal". diabetes.medicinematters.com. Retrieved 2 February 2024.
  11. ^ "»Saxenda - ¿Qué es? - Efecto Rebote - Testimonios" [»Saxenda - What is it? - Rebound Effect - Testimonials] (in Spanish). 2023-10-04. Retrieved 2024-02-02.
From Wikipedia, the free encyclopedia

[1] [2] [3] [4] [5] [6] [7] [8]

Saxenda and Liraglutide

Saxenda is an injectable medication that is recommended for those patients (adults) who are overweight or suffer from other related diseases such as obesity.

The injection is the injectable presentation for the medication liraglutide, which is used to treat blood sugar disorders in patients, the majority of whom are obese or diabetics.

Liraglutide is a drug that is designed to control and manage sugar levels within an individual, it is used to medicate and help people with type 2 diabetes or obesity.

Obesity

Obesity is a chronic illness that has harmed hundreds of people for a long time. It is the buildup of fat within the human body that is detrimental to one's health.

Consequences or Negative effects:

Like all medications, this one has consequences or side effects when stopped, even though it has helped a lot of people.

Digestive Problems

In the Journal of Endocrinology, Metabolism and Diabetes of South Africa, [9] according to L. Lambert, "During clinical trials, gastrointestinal reactions were the most commonly reported adverse reactions." These consist of constipation, diarrhea, vomiting, and nausea.

Rebound effect / Weight gaining

In the Medicine Matters - Diabetes website, [10] they discussed how Bodyweight rebounds after the withdrawal of the medication:

“The researchers found that people who lost the most weight while taking semaglutide tended to then regain the most after stopping it, although they still retained a larger reduction from baseline than participants who had lost less weight during the treatment period.”

The issue with this medication is that, [11] similar to other medicines, it does not work like magic; instead, the effectiveness of the medication depends on how well the person taking it is managing it. Long-term medication effects end, and maintaining your well-being depends entirely on maintaining a regular schedule and leading a balanced, healthy life. After stopping the medication, the rebound effect happens in people who do not follow a healthy diet and routine.


  1. ^ "Can You Maintain Weight-Loss After Saxenda?". www.ukmeds.co.uk. Retrieved 2 February 2024.
  2. ^ Goodman, Brenda (5 October 2023). "Researchers link popular weight loss drugs to serious digestive problems for 'hundreds of thousands' worldwide". CNN. Retrieved 1 February 2024.
  3. ^ Henderson, Laura (23 January 2023). O'Loan, James (ed.). "The Side Effects of Stopping Saxenda | Withdrawal Symptoms". myBMI. Retrieved 1 February 2024.
  4. ^ McDermid, Eleanor. "Bodyweight rebounds after semaglutide withdrawal". diabetes.medicinematters.com. Retrieved 1 February 2024.
  5. ^ Romantsova, Tatiana Ivoanova (25 April 2018). "Analog glyukagonopodobnogo peptida-1 liraglutid (Saksenda®): mekhanizm deystviya, effektivnost' v lechenii ozhireniya" Аналог глюкагоноподобного пептида-1 лираглутид (Саксенда®): механизм действия, эффективность в лечении ожирения [Glucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, effectiveness in the treatment of obesity]. Ožirenie i Metabolizm. 15 (1): 3–11. doi: 10.14341/omet201813-11. Retrieved 2024-02-01.
  6. ^ "Prescription Weight-Loss Medicine | Saxenda® (liraglutide) injection 3mg". www.saxenda.com. Retrieved 1 February 2024.
  7. ^ Nuffer, Wesley A.; Trujillo, Jennifer M. (October 2015). "Liraglutide: A New Option for the Treatment of Obesity". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 35 (10): 926–934. doi: 10.1002/phar.1639. PMID  26497479. S2CID  23968739.
  8. ^ Kelly, Aaron S.; Auerbach, Pernille; Barrientos-Perez, Margarita; Gies, Inge; Hale, Paula M.; Marcus, Claude; Mastrandrea, Lucy D.; Prabhu, Nandana; Arslanian, Silva (28 May 2020). "A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity". New England Journal of Medicine. 382 (22): 2117–2128. doi: 10.1056/NEJMoa1916038. ISSN  0028-4793. PMID  32233338.
  9. ^ Lambert, L (2021). "Focus on Saxenda® solution for injection". Journal of Endocrinology, Metabolism and Diabetes of South Africa. 25.1 (2021): 8–10. doi: 10.1056/NEJMoa1916038. PMID  32233338. Retrieved 2 February 2024.
  10. ^ McDermid, Eleanor (9 May 2022). "Bodyweight rebounds after semaglutide withdrawal". diabetes.medicinematters.com. Retrieved 2 February 2024.
  11. ^ "»Saxenda - ¿Qué es? - Efecto Rebote - Testimonios" [»Saxenda - What is it? - Rebound Effect - Testimonials] (in Spanish). 2023-10-04. Retrieved 2024-02-02.

Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook